Fox Run Management L.L.C. Buys 2,830 Shares of Ascendis Pharma A/S $ASND

Fox Run Management L.L.C. lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 169.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,496 shares of the biotechnology company’s stock after buying an additional 2,830 shares during the period. Fox Run Management L.L.C.’s holdings in Ascendis Pharma A/S were worth $959,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth about $26,000. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $36,000. Jones Financial Companies Lllp boosted its position in shares of Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares during the period. Global Retirement Partners LLC boosted its position in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares during the period. Finally, Quadrant Capital Group LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth about $74,000.

Ascendis Pharma A/S Stock Performance

ASND opened at $209.79 on Thursday. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $250.74. The firm has a market capitalization of $13.09 billion, a PE ratio of 24.20 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The business’s 50-day simple moving average is $232.61 and its 200 day simple moving average is $223.58.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 12.85 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jean Jacques Bienaime bought 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Wall Street Analyst Weigh In

ASND has been the subject of several recent research reports. Bank of America upped their price objective on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Evercore reaffirmed an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.